Potential Promising Therapy for Parkinson's disease

 

Synuclere^™ is our compound for the treatment of Parkinson's disease and is in late pre-clinical stage of development. Research for this project has been partially funded by The Michael J. Fox Foundation for Parkinson's Research LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) award program.

 

Synuclere^™ has been shown in vitro and in vivo to prevent the formation and accumulation of alpha-synuclein deposits and aggregates believed to be important in the formation and/or progression of Parkinson's disease.

 

ProteoTech research has shown that Synuclere^™ is well positioned to address a large and growing unmet need for people who suffer from Parkinson's disease and other forms of Lewy Body dementia.

 

ProteoTech’s Parkinson's Program
	Presented at International Parkinson's Meeting, December 2007 Download Poster (PDF)